Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

BACKGROUND: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort of the phase II Rare Oncology Agnostic Research...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., Ilankumaran, P., Burgess, P., Romero Salas, T., Keam, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338780/
https://www.ncbi.nlm.nih.gov/pubmed/35026411
http://dx.doi.org/10.1016/j.annonc.2021.12.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338780/
https://www.ncbi.nlm.nih.gov/pubmed/35026411
http://dx.doi.org/10.1016/j.annonc.2021.12.014

Ejemplares similares